查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067734

伊波拉市場規模、佔有率和趨勢分析報告：按類型、地區和細分市場預測（2026-2033 年）

Ebola Market Size, Share & Trends Analysis Report By Type (By Therapeutic (Product Type, Route of Administration, Procurement Channel), By Diagnostic (Test Type, End Use)), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

伊波拉市場概況

據估計，2025 年全球伊波拉市場價值為 12 億美元，預計從 2026 年的 12.9 億美元成長到 2033 年的 22.7 億美元，2026 年至 2033 年的複合年成長率為 8.3%。

到 2025 年，北美伊波拉市場將佔全球市場佔有率的 40.9%，成為全球最大的市場佔有率。

由於全部區域日益重視感染疾病防範、免疫接種計畫和快速反應醫療基礎設施，市場正經歷持續成長。醫療機構正優先考慮疫苗接種策略，以提高疫情控制效率並降低疫情期間的死亡率。

Ervebo 和 Zabdeno/Mvabea 等已通過核准疫苗的商業化顯著提升了在非洲和其他脆弱地區大規模部署疫苗的能力。低溫運輸基礎設施的改善、緊急醫療後勤的加強以及對病毒性出血熱風險的意識提高，進一步促進了疫苗的供應和應對準備。醫療服務提供者也越來越重視為第一線工作人員和易受疫情影響的弱勢群體提供快速免疫接種。例如，2026 年 5 月，世界衛生組織 (世衛組織) 宣布剛果民主共和國和烏干達的伊波拉出血熱疫情構成「國際關注的突發公共衛生事件」(PHEIC)，以應對邦迪布焦病毒株的迅速傳播。據世衛組織稱，截至 2026 年 5 月 16 日，剛果民主共和國伊圖裡省至少三個衛生區報告了 246 例疑似病例和 80 例疑似死亡病例。在烏干達，確診了兩例與剛果民主共和國旅行相關的病例，並在採集的13份檢體中檢體檢測出邦迪布焦病毒。這次疫情也導致4名醫護人員死亡，凸顯了在全部區域提高疫苗接種率、加強疫情防控準備和強化感染控制措施的迫切需求。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：伊波拉市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：伊波拉市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測和趨勢分析（按類型，2021-2033 年 / 十億美元）
  • 治療方法
  • 診斷

第5章：伊波拉市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第6章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Merck & Co.
    • Johnson & Johnson
    • Regeneron Pharmaceuticals
    • Ridgeback Biotherapeutics
    • Cepheid
    • altona Diagnostics
    • OraSure Technologies
    • BioFire Diagnostics
    • Bavarian Nordic
    • Gilead Sciences
Product Code: GVR-4-68040-925-1

Ebola Market Summary

The global Ebola market size was estimated at USD 1.20 billion in 2025 and is projected to grow from USD 1.29 billion in 2026 to USD 2.27 billion by 2033, growing at a CAGR of 8.3% from 2026 to 2033. The North America Ebola market held the largest global share of 40.9% in 2025.

The market is witnessing sustained growth due to the increasing emphasis on outbreak preparedness, preventive immunization programs, and rapid-response healthcare infrastructure across high-risk regions. Healthcare organizations are prioritizing vaccination strategies to strengthen epidemic containment efficiency and reduce mortality rates during outbreaks.

The commercial availability of approved vaccines such as Ervebo and Zabdeno/Mvabea has significantly improved large-scale deployment capabilities across Africa and other vulnerable regions. Expanding cold-chain infrastructure, improvements in emergency healthcare logistics, and rising awareness regarding viral hemorrhagic fever transmission risks are further supporting vaccine accessibility and preparedness initiatives. Healthcare providers are also increasingly focusing on rapid immunization coverage for frontline healthcare workers and vulnerable populations exposed to outbreak environments. For instance, in May 2026, the World Health Organization declared the Ebola disease outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern (PHEIC) following the rapid spread of the Bundibugyo virus strain. The organization reported 246 suspected cases and 80 suspected deaths across at least 3 health zones in Ituri Province, DRC, as of 16 May 2026. In Uganda, 2 confirmed cases linked to travel from DRC were identified, while 8 out of 13 collected samples tested positive for the Bundibugyo virus. The outbreak also resulted in 4 deaths among healthcare workers, highlighting the urgent need for expanded vaccination coverage, outbreak preparedness, and infection control programs across affected regions.

Global Ebola Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Ebola market report based on type and region:

  • Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Therapeutic
    • Product Type
  • Vaccine
    • ERVEBO
    • Zabdeno/Mvabea
  • Monoclonal Antibodies
    • Inmazeb
    • Ebanga
  • Supportive Care Therapies
    • Route of Administration
  • Intravenous (IV)
  • Intramuscular (IM)
  • Other
    • Procurement Channel
  • Public
  • Private
  • Diagnostic
    • Test Type
  • Molecular Diagnostic Tests
    • RT-PCR Molecular Diagnostic Tests
    • Real-Time RT-PCR Assays
    • Others
  • Rapid Diagnostic Tests
  • Immunodiagnostic Assays
  • Others
    • End Use
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Government & Public Health Agencies
  • Research Institutes
  • NGOs & International Health Organizations
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Ebola Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Ebola Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
  • 4.4. Therapeutic
    • 4.4.1. Therapeutic Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.2. Product Type
      • 4.4.2.1. Product Type Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.2. Vaccine
        • 4.4.2.2.1. Vaccine Market, 2021 - 2033 (USD Million/Billion)
        • 4.4.2.2.2. ERVEBO
          • 4.4.2.2.2.1. ERVEBO Market, 2021 - 2033 (USD Million/Billion)
        • 4.4.2.2.3. Zabdeno/Mvabea
          • 4.4.2.2.3.1. Zabdeno/Mvabea Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.3. Monoclonal Antibodies
        • 4.4.2.3.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Million/Billion)
        • 4.4.2.3.2. Inmazeb
          • 4.4.2.3.2.1. Inmazeb Market, 2021 - 2033 (USD Million/Billion)
        • 4.4.2.3.3. Ebanga
          • 4.4.2.3.3.1. Ebanga Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.4. Supportive Care Therapies
        • 4.4.2.4.1. Supportive Care Therapies Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.3. Route of Administration
      • 4.4.3.1. Route of Administration Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.3.2. Intravenous (IV)
        • 4.4.3.2.1. Intravenous (IV) Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.3.3. Intramuscular (IM)
        • 4.4.3.3.1. Intramuscular (IM) Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.3.4. Other
        • 4.4.3.4.1. Other Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.4. Procurement Channel
      • 4.4.4.1. Procurement Channel Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.4.2. Public
        • 4.4.4.2.1. Public Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.4.3. Private
        • 4.4.4.3.1. Private Market, 2021 - 2033 (USD Million/Billion)
  • 4.5. Diagnostic
    • 4.5.1. Diagnostic Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.2. Test Type
      • 4.5.2.1. Test Type Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.2. Molecular Diagnostic Tests
        • 4.5.2.2.1. Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
        • 4.5.2.2.2. RT-PCR Molecular Diagnostic Tests
          • 4.5.2.2.2.1. RT-PCR Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
        • 4.5.2.2.3. Real-Time RT-PCR Assays
          • 4.5.2.2.3.1. Real-Time RT-PCR Assays Market, 2021 - 2033 (USD Million/Billion)
        • 4.5.2.2.4. Others
          • 4.5.2.2.4.1. Others Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.3. Rapid Diagnostic Tests
        • 4.5.2.3.1. Rapid Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.4. Immunodiagnostic Assays
        • 4.5.2.4.1. Immunodiagnostic Assays Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.5. Others
        • 4.5.2.5.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3. End Use
      • 4.5.3.1. End Use Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.3.2. Hospitals & Clinics
        • 4.5.3.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.3.3. Diagnostic Laboratories
        • 4.5.3.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.3.4. Government & Public Health Agencies
        • 4.5.3.4.1. Government & Public Health Agencies Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.3.5. Research Institutes
        • 4.5.3.5.1. Research Institutes Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.3.6. NGOs & International Health Organizations
        • 4.5.3.6.1. NGOs & International Health Organizations Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Ebola Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2025 & 2033
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 5.4. North America
    • 5.4.1. North America Ebola Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million/Billion)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Target Disease Prevalence
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. Reimbursement Framework
      • 5.4.2.5. U.S. Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Reimbursement Framework
      • 5.4.3.5. Canada Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Regulatory Framework
      • 5.4.4.4. Reimbursement Framework
      • 5.4.4.5. Mexico Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5. Europe
    • 5.5.1. Europe Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Target Disease Prevalence
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Reimbursement Framework
      • 5.5.2.5. UK Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. Reimbursement Framework
      • 5.5.3.5. Germany Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Target Disease Prevalence
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Reimbursement Framework
      • 5.5.4.5. France Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Target Disease Prevalence
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Reimbursement Framework
      • 5.5.5.5. Italy Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Target Disease Prevalence
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Reimbursement Framework
      • 5.5.6.5. Spain Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.7. Denmark
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Target Disease Prevalence
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Reimbursement Framework
      • 5.5.7.5. Denmark Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.8. Sweden
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Target Disease Prevalence
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Reimbursement Framework
      • 5.5.8.5. Sweden Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.5.9. Norway
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Target Disease Prevalence
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Reimbursement Framework
      • 5.5.9.5. Norway Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Target Disease Prevalence
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. Reimbursement Framework
      • 5.6.2.5. Japan Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. Reimbursement Framework
      • 5.6.3.5. China Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. Reimbursement Framework
      • 5.6.4.5. India Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Reimbursement Framework
      • 5.6.5.5. Australia Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.6. South Korea
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Target Disease Prevalence
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Reimbursement Framework
      • 5.6.6.5. South Korea Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Target Disease Prevalence
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Reimbursement Framework
      • 5.6.7.5. Thailand Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.7. Latin America
    • 5.7.1. Latin America Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Target Disease Prevalence
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Reimbursement Framework
      • 5.7.2.5. Brazil Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Target Disease Prevalence
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Reimbursement Framework
      • 5.7.3.5. Argentina Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.8. Middle East and Africa
    • 5.8.1. Middle East and Africa Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Target Disease Prevalence
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Reimbursement Framework
      • 5.8.2.5. South Africa Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Target Disease Prevalence
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. Reimbursement Framework
      • 5.8.3.5. Saudi Arabia Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Target Disease Prevalence
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Reimbursement Framework
      • 5.8.4.5. UAE Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Target Disease Prevalence
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Reimbursement Framework
      • 5.8.5.5. Kuwait Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Merck & Co.
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Johnson & Johnson
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Regeneron Pharmaceuticals
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Ridgeback Biotherapeutics
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Cepheid
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. altona Diagnostics
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Product Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. OraSure Technologies
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Product Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. BioFire Diagnostics
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Product Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Bavarian Nordic
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Product Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Gilead Sciences
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Product Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Ebola market, by region, 2021 - 2033 (USD Million/Billion)
  • Table 4 Global Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 5 North America Ebola market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 6 North America Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 7 U.S. Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 8 Canada Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 9 Mexico Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 10 Europe Ebola market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 11 Europe Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 12 UK Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 13 Germany Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 14 France Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 15 Italy Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 16 Spain Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 17 Denmark Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 18 Sweden Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 19 Norway Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 20 Asia Pacific Ebola market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 21 Asia Pacific Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 22 Japan Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 23 China Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 24 India Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 25 Australia Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 26 South Korea Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 27 Thailand Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 28 Latin America Ebola market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 29 Latin America Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 30 Brazil Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 31 Argentina Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 32 Middle East & Africa Ebola market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 33 Middle East & Africa Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 34 South Africa Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 35 Saudi Arabia Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 36 UAE Ebola market, by type, 2021 - 2033 (USD Million/Billion)
  • Table 37 Kuwait Ebola market, by type, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Ebola market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Ebola market dynamics
  • Fig. 11 Ebola market: Porter's five forces analysis
  • Fig. 12 Ebola market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Million/Billion)
  • Fig. 14 Therapeutic market, 2021 - 2033 (USD Million/Billion)
  • Fig. 15 Product Type market, 2021 - 2033 (USD Million/Billion)
  • Fig. 16 Vaccine market, 2021 - 2033 (USD Million/Billion)
  • Fig. 17 ERVEBO market, 2021 - 2033 (USD Million/Billion)
  • Fig. 18 Zabdeno/Mvabea market, 2021 - 2033 (USD Million/Billion)
  • Fig. 19 Monoclonal Antibodies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 20 Inmazeb market, 2021 - 2033 (USD Million/Billion)
  • Fig. 21 Ebanga market, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 Supportive Care Therapies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 23 Route of Administration market, 2021 - 2033 (USD Million/Billion)
  • Fig. 24 Intravenous (IV) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Intramuscular (IM) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 26 Other market, 2021 - 2033 (USD Million/Billion)
  • Fig. 27 Procurement Channel market, 2021 - 2033 (USD Million/Billion)
  • Fig. 28 Public market, 2021 - 2033 (USD Million/Billion)
  • Fig. 29 Private market, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 Diagnostic market, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Test Type market, 2021 - 2033 (USD Million/Billion)
  • Fig. 32 Molecular Diagnostic Tests market, 2021 - 2033 (USD Million/Billion)
  • Fig. 33 RT-PCR Molecular Diagnostic Tests market, 2021 - 2033 (USD Million/Billion)
  • Fig. 34 Real-Time RT-PCR Assays market, 2021 - 2033 (USD Million/Billion)
  • Fig. 35 Others market, 2021 - 2033 (USD Million/Billion)
  • Fig. 36 Rapid Diagnostic Tests market, 2021 - 2033 (USD Million/Billion)
  • Fig. 37 Immunodiagnostic Assays market, 2021 - 2033 (USD Million/Billion)
  • Fig. 38 Others market, 2021 - 2033 (USD Million/Billion)
  • Fig. 39 End Use market, 2021 - 2033 (USD Million/Billion)
  • Fig. 40 Hospitals & Clinics market, 2021 - 2033 (USD Million/Billion)
  • Fig. 41 Diagnostic Laboratories market, 2021 - 2033 (USD Million/Billion)
  • Fig. 42 Government & Public Health Agencies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 43 Research Institutes market, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 NGOs & International Health Organizations market, 2021 - 2033 (USD Million/Billion)
  • Fig. 45 Ebola market revenue, by region
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 U.S. country dynamics
  • Fig. 49 U.S. Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 Canada country dynamics
  • Fig. 51 Canada Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 52 Mexico country dynamics
  • Fig. 53 Mexico Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 54 Europe Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 55 UK country dynamics
  • Fig. 56 UK Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 57 Germany country dynamics
  • Fig. 58 Germany Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 59 France country dynamics
  • Fig. 60 France Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 61 Italy country dynamics
  • Fig. 62 Italy Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 63 Spain country dynamics
  • Fig. 64 Spain Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 65 Denmark country dynamics
  • Fig. 66 Denmark Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 67 Sweden country dynamics
  • Fig. 68 Sweden Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 69 Norway country dynamics
  • Fig. 70 Norway Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 71 Asia Pacific Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 72 Japan country dynamics
  • Fig. 73 Japan Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 74 China country dynamics
  • Fig. 75 China Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 76 India country dynamics
  • Fig. 77 India Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 78 Australia country dynamics
  • Fig. 79 Australia Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 80 South Korea country dynamics
  • Fig. 81 South Korea Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 82 Thailand country dynamics
  • Fig. 83 Thailand Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 84 Latin America Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 85 Brazil country dynamics
  • Fig. 86 Brazil Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 87 Argentina country dynamics
  • Fig. 88 Argentina Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 89 MEA Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 90 South Africa country dynamics
  • Fig. 91 South Africa Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 92 Saudi Arabia country dynamics
  • Fig. 93 Saudi Arabia Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 94 UAE country dynamics
  • Fig. 95 UAE Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 96 Kuwait country dynamics
  • Fig. 97 Kuwait Ebola market, 2021 - 2033 (USD Million/Billion)
  • Fig. 98 Company categorization
  • Fig. 99 Company market position analysis
  • Fig. 100 Strategic framework